Jack Hirsh
Research Subjects
Research Interests
Jack Hirsh has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- John William Eikelboom
McMaster University
5 shared publications Gordon Guyatt
4 shared publicationsJeffrey I. Weitz
Henderson Research Centre and McMaster University, Hamilton, ON, Canada
2 shared publications- Martin O' Donnell
HRB-Clinical Research Facility, National University of Ireland Galway, Galway, Ireland
2 shared publications Shannon M. Bates
From Hamilton Civic Hospitals Research Centre and McMaster University, Hamilton, Ontario, Canada
2 shared publicationsAgnes Y. Y. Lee
From the Henderson Research Centre, and the Department of Medicine, McMaster University, Hamilton, Ontario, Canada
1 shared publication
Latest Publications
- 1 October 2012
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 144 (4) , 944-950.e3
Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial
- 1 October 2012
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 144 (4) , 944-950.e3
Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial
- 1 July 2009
- Published by Elsevier in The Lancet
- Vol. 374 (9686) , 273-275
Clinical experts or methodologists to write clinical guidelines?
- 1 July 2009
- Published by Elsevier in The Lancet
- Vol. 374 (9686) , 273-275
Clinical experts or methodologists to write clinical guidelines?
- 1 August 2008
- Published by Elsevier in The Lancet
- Vol. 372 (9638) , 533-534
Guidelines for anticoagulant use in acute coronary syndromes – Authors' reply
- 1 August 2008
- Published by Elsevier in The Lancet
- Vol. 372 (9638) , 533-534
Guidelines for anticoagulant use in acute coronary syndromes – Authors' reply
- Top Cited Papers
Parenteral Anticoagulants
- 1 May 2008
- Published by Elsevier in The Lancet
- Vol. 371 (9624) , 1559-1561
Guidelines for anticoagulant use in acute coronary syndromes
- 1 May 2008
- Published by Elsevier in The Lancet
- Vol. 371 (9624) , 1559-1561
Guidelines for anticoagulant use in acute coronary syndromes
- 1 November 2006
- Vol. 96 (5) , 547-52
Monitoring unfractionated heparin with the aPTT: time for a fresh look.
Laboratory monitoring is widely recommended to measure the anticoagulant effect of unfractionated heparin and to adjust the dose to maintain levels in the target therapeutic range. The most widely used laboratory assay for monitoring unfractionated heparin therapy is the activated partial thromboplastin time (aPTT). A fixed therapeutic range for the aPTT of 1.5 to 2.5 times the control value has become widely accepted, but the evidence supporting this range is weak and the clinical validity of using the aPTT for predicting thrombotic or bleeding events is questionable. The aPTT test is also affected by numerous preanalytic and analytic variables that are unrelated to the anticoagulant effect of unfractionated heparin, further eroding its potential value for monitoring unfractionated heparin treatment. Unfractionated heparin dose appears to be more important than the aPTT in predicting clinical efficacy. Despite serious limitations, the reliance on the aPTT is likely to continue because of its ready availability and familiarity of clinicians with the test. The focus of clinicians who manage unfractionated heparin therapy should be to ensure that an adequate starting dose of unfractionated heparin is used and that the aPTT method is standardized. Future research efforts should be directed towards developing methods to improve standardization of the aPTT assay for monitoring unfractionated heparin. Direct measures of the concentration of unfractionated heparin in the blood are attractive because these assays are not affected by many of the biologic variables that interfere with the aPTT and may be suitable for automation. However, currently available unfractionated heparin assays are much more expensive than the aPTT, are not widely available, and their validity has not been adequately assessed in clinical outcome studies.
- 1 November 2006
- Vol. 96 (5) , 547-52
Monitoring unfractionated heparin with the aPTT: time for a fresh look.
Laboratory monitoring is widely recommended to measure the anticoagulant effect of unfractionated heparin and to adjust the dose to maintain levels in the target therapeutic range. The most widely used laboratory assay for monitoring unfractionated heparin therapy is the activated partial thromboplastin time (aPTT). A fixed therapeutic range for the aPTT of 1.5 to 2.5 times the control value has become widely accepted, but the evidence supporting this range is weak and the clinical validity of using the aPTT for predicting thrombotic or bleeding events is questionable. The aPTT test is also affected by numerous preanalytic and analytic variables that are unrelated to the anticoagulant effect of unfractionated heparin, further eroding its potential value for monitoring unfractionated heparin treatment. Unfractionated heparin dose appears to be more important than the aPTT in predicting clinical efficacy. Despite serious limitations, the reliance on the aPTT is likely to continue because of its ready availability and familiarity of clinicians with the test. The focus of clinicians who manage unfractionated heparin therapy should be to ensure that an adequate starting dose of unfractionated heparin is used and that the aPTT method is standardized. Future research efforts should be directed towards developing methods to improve standardization of the aPTT assay for monitoring unfractionated heparin. Direct measures of the concentration of unfractionated heparin in the blood are attractive because these assays are not affected by many of the biologic variables that interfere with the aPTT and may be suitable for automation. However, currently available unfractionated heparin assays are much more expensive than the aPTT, are not widely available, and their validity has not been adequately assessed in clinical outcome studies.
- 15 January 2005
- Published by American Society of Hematology in Blood
- Vol. 105 (2) , 453-463
New anticoagulants
Anticoagulants are pivotal agents for prevention and treatment of thromboembolic disorders. Limitations of existing anticoagulants, vitamin K antagonist and heparins, have led to the development of newer anticoagulant therapies. These anticoagulants have been designed to target specific coagulation enzymes or steps in the coagulation pathway. New anticoagulants that are under evaluation in clinical trials include: (1) inhibitors of the factor VIIa/tissue factor pathway; (2) factor Xa inhibitors, both indirect and direct; (3) activated protein C and soluble thrombomodulin; and (4) direct thrombin inhibitors. Although most of these are parenteral agents, several of the direct inhibitors of factor Xa and thrombin are orally active. Clinical development of these therapies often starts with studies in the prevention of venous thrombosis before evaluation for other indications, such as prevention of cardioembolism in patients with atrial fibrillation or prosthetic heart valves. At present, the greatest clinical need is for an oral anticoagulant to replace warfarin for long-term prevention and treatment of patients with venous and arterial thrombosis. Ximelagatran, an oral direct thrombin inhibitor, is the first of a series of promising new agents that might fulfill this need. Large phase 3 trials evaluating ximelagatran for the secondary prevention of venous thromboembolism and prevention of cardioembolic events in patients with atrial fibrillation have been completed.
- 15 January 2005
- Published by American Society of Hematology in Blood
- Vol. 105 (2) , 453-463
New anticoagulants
Anticoagulants are pivotal agents for prevention and treatment of thromboembolic disorders. Limitations of existing anticoagulants, vitamin K antagonist and heparins, have led to the development of newer anticoagulant therapies. These anticoagulants have been designed to target specific coagulation enzymes or steps in the coagulation pathway. New anticoagulants that are under evaluation in clinical trials include: (1) inhibitors of the factor VIIa/tissue factor pathway; (2) factor Xa inhibitors, both indirect and direct; (3) activated protein C and soluble thrombomodulin; and (4) direct thrombin inhibitors. Although most of these are parenteral agents, several of the direct inhibitors of factor Xa and thrombin are orally active. Clinical development of these therapies often starts with studies in the prevention of venous thrombosis before evaluation for other indications, such as prevention of cardioembolism in patients with atrial fibrillation or prosthetic heart valves. At present, the greatest clinical need is for an oral anticoagulant to replace warfarin for long-term prevention and treatment of patients with venous and arterial thrombosis. Ximelagatran, an oral direct thrombin inhibitor, is the first of a series of promising new agents that might fulfill this need. Large phase 3 trials evaluating ximelagatran for the secondary prevention of venous thromboembolism and prevention of cardioembolic events in patients with atrial fibrillation have been completed.